Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 57 of 57 matching drugs for CTLA4 — including drugs targeting any of its 8 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab CTLA4 Direct 4
nivolumab, ipilimumab CTLA4 Direct 4
paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin, nab-paclitaxel (paclitaxel-albumin) + carboplatin, oxaliplatin + 5-fluorouracil (5fu) + leucovorin (calcium folinate/folinic acid), durvalumab, tremelimumab, nab-paclitaxel (paclitaxel-albumin) + gemcitabine, cisplatin + 5-fluorouracil (5fu) CTLA4 Direct 4
biospecimen collection, computed tomography, echocardiography, ipilimumab, magnetic resonance imaging, nivolumab CTLA4 Direct 3
bms-986207, nivolumab, ipilimumab CTLA4 Direct 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel CTLA4 Direct 2
durvalumab, tremelimumab, sbrt CTLA4 Direct 2
ipilimumab CTLA4 Direct 2
ly3022855, durvalumab, tremelimumab CTLA4 Direct 2
nivolumab, ipilimumab, cobimetinib CTLA4 Direct 2
selumetinib, medi4736, tremelimumab CTLA4 Direct 2
stereotactic body radiotherapy, ipilimumab, nivolumab, pembrolizumab or atezolizumab CTLA4 Direct 2
trabectedin, ipilimumab, nivolumab CTLA4 Direct 2
anetumab ravtansine, biopsy, biospecimen collection, gemcitabine hydrochloride, ipilimumab, nivolumab CTLA4 Direct 1
anti-sema4d monoclonal antibody vx15/2503, ipilimumab, nivolumab, surgery CTLA4 Direct 1
cabozantinib, durvalumab, tremelimumab CTLA4 Direct 1
cobimetinib, olaparib, onvansertib, azenosertib, saruparib, tremelimumab CTLA4 Direct 1
contrast-enhanced magnetic resonance imaging, ipilimumab, nivolumab, novottf-100a device, quality-of-life assessment, questionnaire administration, radiation therapy, temozolomide CTLA4 Direct 1
cyclophosphamide, nivolumab, ipilimumab, gvax pancreas vaccine, crs-207, crs-207 CTLA4 Direct 1
durvalumab 50 mg/ml, tremelimumab CTLA4 Direct 1
durvalumab, carboplatin auc 2/paclitaxel, external beam radiation (ebrt), esophagogastrectomy, tremelimumab CTLA4 Direct 1
durvalumab, doxorubicin-eluting beads, tace, bevacizumab, tremelimumab CTLA4 Direct 1
durvalumab, gemcitabine, nab paclitaxel, tremelimumab, propranolol, cisplatin CTLA4 Direct 1
durvalumab, hypofractionated radiation therapy, stereotactic body radiation therapy, tremelimumab CTLA4 Direct 1
durvalumab, laboratory biomarker analysis, surgical procedure, tremelimumab CTLA4 Direct 1
durvalumab, tremelimumab, folfiri protocol CTLA4 Direct 1
durvalumab, tremelimumab, yttrium-90 radioembolisation CTLA4 Direct 1
fluorouracil, intensity-modulated radiation therapy, ipilimumab, nivolumab, oxaliplatin, therapeutic conventional surgery CTLA4 Direct 1
gemcitabine, nab-paclitaxel, durvalumab, tremelimumab CTLA4 Direct 1
gemcitabine, nab-paclitaxel, nivolumab, ipilimumab, sbrt CTLA4 Direct 1
il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells, ipilimumab, nivolumab, quality-of-life assessment, questionnaire administration CTLA4 Direct 1
incagn01876, nivolumab, ipilimumab CTLA4 Direct 1
incagn01949, nivolumab, ipilimumab CTLA4 Direct 1
ipilimumab, best supportive care (bsc) CTLA4 Direct 1
ipilimumab, gemcitabine hydrochloride, laboratory biomarker analysis CTLA4 Direct 1
ipilimumab, laboratory biomarker analysis, nivolumab, temozolomide CTLA4 Direct 1
ipilimumab, nivolumab CTLA4 Direct 1
ipilimumab, pancreatic cancer vaccine CTLA4 Direct 1
ipilimumab, vaccine, folfirinox CTLA4 Direct 1
kras peptide vaccine, nivolumab, ipilimumab CTLA4 Direct 1
medi4736 + tremelimumab, medi4736 + tremelimumab, medi4736, tremelimumab, medi4736+tremelimumab, medi4736 + tremelimumab CTLA4 Direct 1
medi4736, tremelimumab CTLA4 Direct 1
nivolumab, bevacizumab, ipilimumab CTLA4 Direct 1
nivolumab, ipilimumab, cisplatin, fluorouracil CTLA4 Direct 1
nivolumab, ipilimumab, oxaliplatin, capecitabine, leucovorin, fluorouracil CTLA4 Direct 1
nivolumab, ipilimumab, radiation therapy (rt) CTLA4 Direct 1
nivolumab, ipilimumab, relatlimab, daratumumab CTLA4 Direct 1
nivolumab, ipilimumab, stereotactic body radiation therapy, low dose irradiation CTLA4 Direct 1
nivolumab, nivolumab, ipilimumab CTLA4 Direct 1
nivolumab-placebo, nivolumab, ipilimumab-placebo, ipilimumab, surgery CTLA4 Direct 1
radiation, cisplatin, durvalumab, tremelimumab CTLA4 Direct 1
tadalafil, pembrolizumab, ipilimumab, crs-207 CTLA4 Direct 1
temozolomide, conformal brain radiation therapy, nivolumab, ipilimumab, bevacizumab, 5-day temozolomide, 5-day temozolomide, lomustine, nivolumab monotherapy CTLA4 Direct 1
thoracic radiation therapy, ipilimumab, nivolumab CTLA4 Direct 1
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) PIK3R1 SSL via PIK3R1 1
enzastaurin, lomustine PIK3R1 SSL via PIK3R1 1
enzastaurin, temozolomide, radiation therapy PIK3R1 SSL via PIK3R1 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.